High mortality and low survival rates for pancreatic ductal adenocarcinoma (PDAC) mainly result from the delay in diagnosis and treatment. Therefore, there is an urgent need to identify early PDAC biomarkers and new therapeutic targets. In this study, we applied a commonly used systems biology approach, the weighted gene co-expression network analysis (WGCNA), on lncRNA expression data. Eleven lncRNAs, namely A2M-AS1, DLEU2, LINC01133, LINC00675, MIR155HG, SLC25A25-AS1, LINC01857, LOC642852 (LINC00205), ITGB2-AS1, TSPOAP1-AS1 and PSMB8-AS1 have been identified and validated on an independent PDAC expression dataset. Furthermore, we characterized them by functional and pathway enrichment analysis and identified which lncRNAs showed differential expression, differential promoter methylation levels and copy number alterations between normal and PDAC samples. Finally, we also performed a survival analysis and identified A2M-AS1, LINC01133, LINC00205 and TSPOAP1-AS1 as prognostic biomarkers for PDAC. Interestingly, although only a few cancer-associated lncRNAs have been functionally characterized, LINC00675 and LINC01133 lncRNAs have already been demonstrated to be involved in PDAC development and progression. Therefore, our results provide new potential diagnostic/prognostic biomarkers and therapeutic targets for PDAC that deserve to be further investigated. Moreover, these lncRNAs may improve the understanding about molecular pathogenesis of PDAC.
Introduction
Pancreatic ductal adenocarcinoma (PDAC), that accounts for 85% of pancreatic cancer cases, is the twelfth most common type of malignancy and the third leading cause of cancer deaths (1) . Incidence rates of pancreatic cancer are increasing while most cancer types present stable or declining trends. In particular, the 5-year relative survival for pancreatic cancer is currently 8% with a slight increase compared to the past, in contrast to the steady increase in survival for most cancers (1) . A major factor contributing to this poor prognosis is the inability to detect PDAC in an early stage due to the asymptomatic and invasive nature of the disease at advanced stages. In addition, currently adopted drugs have yielded only modest improvements in survival (2) . Therefore, further investigations regarding molecular mechanisms underlying PDAC onset and development are essential for improvements in diagnosis and treatment. Currently, cancer research is also focusing on the identification and validation of early diagnostic biomarkers, prognostic biomarkers able to identify patients that may better respond to chemotherapy, as well as new therapeutic targets and so more efficient treatments.
Many studies have explored biomarkers both in body fluids and tumour biopsies, suggesting many candidate RNAs and proteins as early diagnostic and prognostic biomarkers of PDAC, but their performances remain to be validated in larger patient cohorts (3) . Such markers include gain-of-function and loss-offunction mutations in KRAS, CDKN2A, TP53 and SMAD4 genes, epigenetic alterations, dysregulated expression of many miRNAs and other non-coding RNAs, cell-free circulating tumour DNAs and exosomal RNAs and proteins (4) . Even the carbohydrate antigen 19-9 (CA19-9), a widely used serum biomarker for PDAC, has limitations related to its sensitivity and specificity (5) . Other candidate biomarkers have been excluded as PDAC prognosticators, despite their initial expectations (6, 7) .
Recently, the need to identify reliable biomarkers led researchers to explore the role of a class of RNA poorly investigated in tumour onset and progression, i.e. the long non-coding RNAs (lncRNAs). In fact, accumulating recent evidences show that lncRNAs play critical roles in many biological processes, their profiles are cell-and tumour-specific, and may be used as diagnostic markers or therapeutic targets in many cancer types (8, 9) . Regarding PDAC, some lncRNAs are abnormally expressed and may be involved in cell growth, apoptosis, invasion, metastasis and angiogenesis and epithelial-mesenchymal transition (EMT) (10, 11) . However, the research about the lncRNAs with potential diagnostic or prognostic value in PDAC is still at the beginning, especially if compared to the studies on gene mutations and on miRNAs.
We previously identified new potential diagnostic and prognostic biomarkers for PDAC, besides others that were previously reported, by applying the weighted gene co-expression network analysis (WGCNA) on gene and on microRNA expression data (12, 13) . WGCNA is a systems biology approach increasingly adopted in molecular oncology (14, 15) . In particular, based on expression data, the WGCNA approach allows the identification of co-expressed genes, i.e. genes with highly similar expression profiles among different samples. By constructing networks based on these co-expressed genes (so called 'co-expression networks'), WGCNA can cluster genes into modules, that is subregions of the network with strongly co-expressed genes. Since a module is generally composed of genes involved in well-defined pathways, it can be associated with specific functions, implicated in physiological or pathological processes. Moreover, it is possible to identify the most central genes of a module, called hub genes, that represent the module and that are good candidates to influence the traits of interest. By comparing two co-expression networks based on normal and disease-associated expression data, it is possible to identify the distinguishing modules, and within them, the most relevant hub elements (genes, miRNAs or lncRNAs) that therefore are able to distinguish between 'normal' and 'disease' conditions. Very recently, WGCNA has been used also to study lncRNA profiles in different cancer types (16, 17) .
Here, for the first time, we applied this method on lncRNA expression data in PDAC in order to provide potential diagnostic/prognostic biomarkers and therapeutic targets, and also improve understanding about PDAC carcinogenesis. Moreover, we further analyzed the candidate biomarkers by bound miRNAs, copy number variations, differential expression and methylation in normal and PDAC tissues and verified also their role as prognostic biomarker by survival analyses.
Materials and methods

LncRNA expression data in PDAC samples
Two microarray-based expression datasets were downloaded from the NCBI Gene Expression Omnibus (GEO). GSE15471 and GSE16515 datasets contain expression data from in total 55 normal pancreatic and 75 PDAC tissue samples. By adopting the training-validation approach (10), we used the first dataset as training set for discovery of candidate lncRNA biomarkers, while the second one as validation set in order to independently confirm training set results, by conducting the same analysis. Both datasets consist of expression data from PDAC tissue samples and adjacent normal tissue samples obtained during surgical procedures. In particular, GSE15471 dataset consists of 39 PDAC and 39 normal samples, whereas GSE16515 dataset consists of 16 PDAC and 16 normal samples, along with further 20 samples consisting of only tumour data. Moreover, both datasets were produced using Affymetrix Human Genome U133 Plus 2.0 microarray platform. Raw CEL files from each microarray dataset were pre-processed identically with the R package oligo for background correction and normalization. Then, we selected only probes for lncRNAs from the Affymetrix U133 Plus 2.0 microarray platform. To this aim, first we downloaded the latest version of NetAffx Annotation File (Release 36) from Affymetrix website. For each microarray probeset ID, it includes the gene symbol and name, Ensembl gene ID, Refseq transcript ID and other useful information. Second, similarly to previous studies (10), we retained probes labelled as 'NR_', 'long non-coding', 'long intergenic', 'lincRNA', 'antisense RNA' and filtered out pseudogenes, rRNAs, microRNAs, tRNAs, snRNAs and snoRNAs. Finally, we obtained a microarray subset consisting of 5087 annotated lncRNA transcripts that we used for the following analyses. Training and validation datasets, now containing only lncRNA expression data, were subdivided into Normal and PDAC subsets, creating four datasets in total, that we used for the subsequent differential expression and WGCNA analyses. However, it is not recommended to attempt WGCNA on a dataset consisting of fewer than 20 samples in order to obtain more robust and refined results. Since Normal subset of the validation dataset only consist of 16 samples, we discarded it and therefore we used the Normal subset of the training dataset (39 samples) as reference dataset for all WGCNA analyses. From each of the three remaining subsets, we removed outlier samples that, according to the standardized connectivity (Z.K) method suggested by WGCNA authors, are those with Z.K score <−2 (18) . As required by WGCNA method, we also checked whether the Normal subset was comparable with PDAC subsets of training and validation datasets by calculating the correlation of both the expression level and the connectivity of each lncRNA between each pair of expression subsets by using the softConnectivity function from R package WGCNA. These values should be positive and with significant P-values. By applying the pickSoftThreshold function, we also verified whether the networks arising from the three subsets had a scale-free topology, as previously defined (19) . Regarding differential expression analysis, we used R limma package in order to identify lncRNA probes with significant expression differences using a P-value of <0.05. The Benjamini and Yekutieli correction was applied to adjust the raw P-value for multiple testing for the false discovery rate and to calculate the fold change (FC). These data have been used to generate Heatmaps, MA, Manhattan, and Volcano plots for visual representation of differential expression patterns.
Modules and hub lncRNAs in lncRNA co-expression networks
Three co-expression networks, based on lncRNA expression profiles of the Normal subset, the PDAC subset in training dataset and the PDAC subset in validation dataset, were constructed using the WGCNA package in R, using standard procedures (20) . Briefly, we created the Pearson's correlation matrix for all pair-wise lncRNAs and subsequently, a weighted adjacency matrix using the soft-thresholding parameters calculated by the above-mentioned pickSoftThreshold function. This parameter emphasizes strong correlations between lncRNAs whereas penalizes weak correlations. Then, the adjacency matrix has been transformed into a topological overlap matrix, which represents the connectivity of each lncRNA in the network. Hierarchical clustering analysis of the topological overlap matrix was also performed to identify network modules present in the Normal subset of the training expression dataset, used here as reference set. For the clustering, we applied the R function cutreeHybrid, using a minimum module size of 50. Subsequently, in order to highlight differences between Normal and PDAC networks, the identified modules in the reference dataset have been compared to modules in PDAC networks by using the WGCNA module preservation analysis. In particular, we performed a permutation test by applying the function modulePreservation from the WGCNA package, to assess the preservation level of a module between Normal and a PDAC (21), the resulting Z-scores below 10 indicate a low preservation of a module between the normal and tumour conditions. Note that, since Grey module contains lncRNAs not assigned to any module and Gold module is created only for statistical aims, they should be not considered for further analyses. Within not preserved modules, we identified the highly connected lncRNAs, i.e. hub lncRNAs, by measuring the network distance of a lncRNA to the mean expression profile of a module (module eigengene), by applying WGCNA functions. Therefore, closest lncRNAs can be considered hub elements of the module. We selected the first 20 hub lncRNAs for further analyses in each not-preserved module. Only hub lncRNAs, identified by WGCNA using the training dataset and confirmed by validation dataset, assemble the list of candidate lncRNA biomarkers for PDAC that are worth being further analyzed.
Functional annotations of candidate lncRNA biomarkers
In order to facilitate the interpretation of the biological mechanisms related to the hub lncRNAs in PDAC that we identified and validated, we used LncRNA2Function tool (22) that infers lncRNA function annotations (Gene Ontology terms, KEGG, Reactome, NetPath, PID, INOH and BioCarta pathways) based on those of significantly co-expressed protein-coding genes in public expression datasets.
Prediction of the involvement of candidate lncRNAs in PDAC
Moreover, in order to identify which lncRNAs are potentially involved in pancreatic cancer, we used FARNA tool (23) , that predicts disease annotations of lncRNAs based on expression levels of transcription factors and co-factors known to regulate lncRNA transcription. In order to predict the involvement of lncRNAs in various diseases, this tool exploits data collected in KEGG Orthology Based Annotation System (KOBAS) database, which integrates KEGG DISEASE, GAD and NHGRI GWAS Catalog disease databases. Only statistically significant results of these analyses are reported (P < 0.05).
Identification and functional annotation of miRNAs targeting lncRNAs
Experimentally validated miRNAs targeting candidate lncRNA biomarkers have been obtained from DIANA-LncBase v2 (24) and starBase v2.0 (25) databases that collect experimentally supported miRNA-lncRNA interactions, derived from manually curated publications and large-scale CLIP-Seq data. Next, a functional enrichment analysis of these miRNAs has been performed, in order to facilitate the interpretation of their biological mechanisms. In particular, we used the DIANA-miRPath v3.0 tool (26) that is able to identify statistically enriched KEGG pathways based on experimentally validated miRNA-mRNA interactions collected in DIANATarBase v7.0.
Differential expression of lncRNA biomarkers
To investigate the expression of our candidate biomarkers in other normal and tumour pancreatic tissues, we used GEPIA tool (27) . It performs differential expression analyses using RNA-Seq data of a very large cohort (171 normal pancreata and 179 PDAC tissue samples) produced by The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) projects. We selected 'PAAD' (pancreatic adenocarcinoma) dataset for tumour expression data. LncRNAs with absolute log2 Fold Change (|log2FC|) >1 and P-value<0.01 are considered differentially expressed. Y-axes of the plots are in log-scale. We also searched for expression data in literature and in Pancreatic Expression Database (www.pancreasexpression.org) (28) that collects literature expression data from normal and tumour samples of PDAC patients. Regarding this, only statistically significant differences (P < 0.05) are reported.
Differential methylation analysis
We searched for methylation levels of candidate lncRNAs in the MethHC database (29) . This tool allowed us to compare average methylation levels of lncRNA gene promoters in PDAC and matched normal samples using data from TCGA project. P-values < 0.05 were considered significant.
Copy number alteration (CNAs) analysis
The identification of lncRNA genes with significantly high or low copy number in pancreatic cancer samples has been performed using oncoNcRNA tool (30) . It is based on TCGA data and exploits the tool GISTIC in order to identify genomic amplifications and deletions. According to GISTIC tool, the amplification and deletion peaks with q-values < 0.25 were considered as significantly altered between tumour and normal samples. The oncoNcRNA tool, based on TCGA expression data in pancreatic cancer (PAAD dataset), can also perform correlation analyses between the expression levels of a lncRNA and its copy number in pancreatic cancer samples. For these correlation analyses, we reported only significant results (P < 0.05).
Survival analyses
Survival analyses were performed by using the GEPIA tool (27) on an independent PDAC dataset present in TCGA and obtained by RNA-seq of 171 patient tissues. Based on this data, GEPIA tool splits the high-expression and low-expression cohorts by the median for the log-rank test (also called Mantel-Cox test). In addition, it calculates the hazard ratios (HR) and their confidence intervals (CI). We performed both overall survival (OS) and disease-free survival analyses. Only the lncRNAs with P < 0.05 were considered statistically significant and potential prognostic biomarkers.
Results
LncRNA expression data
In order to identify candidate lncRNA biomarkers and therapeutic targets for PDAC, in this study we analyzed two microarray-based expression datasets available at NCBI GEO database, i.e. GSE15471 and GSE16515, both consisting of expression data of PDAC tissue samples and adjacent normal tissue samples. The first (and larger) dataset, consisting of 39 normal and 39 tumour samples, has been used as training dataset to identify a list of potential lncRNA biomarkers, while the second one, consisting of 16 normal and 36 tumour samples, has been exploited as validation dataset. Only common candidate lncRNAs have been considered as biomarkers for PDAC. This training-validation approach has been generally adopted in microarray expression data analysis (10) . During processing of expression data, firstly we identified and removed outlier samples, since WGCNA is sensitive to their presence. From GSE15471, we removed normal samples GSM388111 and GSM388097 and the tumour sample GSM388137, while from GSE16515 dataset we filtered out the tumour samples GSM414945 and GSM414962. As a result, the training dataset consisted of 37 normal and 38 tumour samples, whereas the validation dataset was composed of 34 PDAC tissue samples. On these datasets, we performed differential expression analysis using R limma package. In the training dataset, we identified five lncRNAs upregulated in PDAC compared to normal tissue samples (Supplementary Figure 1A , available at Carcinogenesis Online). In the validation dataset, three lncRNAs were upregulated while two lncRNAs were downregulated in PDAC compared to normal tissue samples (Supplementary Figure 1B, Since WGCNA requires more than 20 samples to construct a network and to obtain reliable results, the sample size of normal subset of the validation dataset is not sufficient, and therefore discarded. As consequence, we used the normal subset of the training dataset as reference dataset for all WGCNA analyses. As required by WGCNA, we also verified that the Normal subset was comparable to both PDAC subsets, in fact the overall lncRNA expression correlations and the overall lncRNA connectivity were positive and with significant P-values, both regarding the training dataset (0.98, P < 1e−200 and 0.76, P < 1e−200) and the validation dataset (0.93, P < 1e−200 and 0.63, P < 1e−200) (Supplementary Figure 5 , available at Carcinogenesis Online). These parameters indicate the co-expression level of each lncRNA versus all other lncRNAs, obtained comparing the two datasets. We also verified that the networks to be constructed, based on these three expression subsets, exhibited a scale-free topology, as is required by WGCNA. Generally, metabolic and signalling networks have a scale-free topology, in which some nodes (here lncRNAs) are closer each other than others and are called hub nodes, whereas others are peripheral nodes. Our three networks have correctly this type of topology, since the Scale-free Topology Fit Index reached values above 0.8 for low powers (<30) for all expression subsets. In particular, we obtained soft-threshold powers of 12, 5 and 4 for the Normal subset, the PDAC subset of the training dataset and the PDAC subset of the validation dataset, respectively (Supplementary Figure 6 , available at Carcinogenesis Online).
Modules in Normal network and comparison with PDAC network
By using standard WGCNA procedures, we constructed three weighted lncRNA co-expression networks, and identified modules in the network based on Normal dataset, used as reference. A module is a dense subregion of the network where nodes (here lncRNAs) are strongly connected, that is highly co-expressed. In the Normal network, we identified four modules, labelled by different colours according to WGCNA functions, i.e. Blue, Brown, Yellow and Turquoise composed of 67, 61, 51 and 4218 lncRNAs, respectively ( Figure 1A) . Next, we set out to evaluate whether and which modules in Normal network were preserved in the PDAC network of the training dataset. If they showed altered network properties, they may be related to the development of PDAC. For the identification of lowly preserved modules between Normal and PDAC networks, we calculated a Z-score for each module (Supplementary Table 5 , available at Carcinogenesis Online). Only the module Turquoise was preserved, whereas Blue, Brown and Yellow modules were lowly preserved and, thus, may distinguish normal from pathological conditions. Among them, Blue module showed the lowest preservation level. As expected, Grey and Gold modules, that are special WGCNA modules not to be considered, exhibited low Z-scores ( Figure 1B) . Focusing on the not preserved Blue, Brown and Yellow modules, we set out to identify their central nodes (hub lncRNAs) that well represent these modules, according to WGCNA procedures. In Supplementary  Table 6 , available at Carcinogenesis Online, we showed the top 20 hub lncRNAs that we identified for each not preserved module in the PDAC network. Although these 60 lncRNAs were found exclusively in the PDAC network, so able to distinguish Normal from PDAC networks based on the training expression dataset, they have to be validated using an independent expression dataset.
Validation of the candidate lncRNA biomarkers
Adopting a training-validation approach (10), we used identical WGCNA procedures to compare the Normal network with the PDAC network based on a further and independent expression dataset (validation dataset). Therefore, we identified a second list of candidate lncRNA biomarkers. In particular, the Turquoise, Blue, Brown and Yellow modules were not preserved between the reference Normal network and the PDAC network deriving from the validation dataset ( Figure 1C , Supplementary Table 7 , available at Carcinogenesis Online). Blue module showed the lowest preservation level also in this validation phase. We focused our attention on Blue, Brown and Yellow modules, since they were not preserved both compared to the training and the validation PDAC datasets. Within these three modules we identified further 60 hub lncRNAs (top 20 hub lncRNAs for each module) (Supplementary Table 8 , available at Carcinogenesis Online), according to WGCNA prioritization functions for hub element identification. By comparing the two hub lncRNA lists deriving from training and validation datasets, only 11 elements were common ( Table 1 ). Since these lncRNAs resulted from comparison of two independent PDAC expression datasets, they represent the most reliable lncRNA biomarkers for PDAC among all lncRNAs identified in this study by WGCNA analyses.
Functional annotations of candidate lncRNAs
Since these 11 hub lncRNAs may be involved in the pathogenesis and progression of PDAC, we further studied their possible cellular roles and the biological mechanisms related to PDAC. However, only a few lncRNAs have been functionally characterized. Therefore, we used some recently developed prediction tools about lncRNAs. By applying LncRNA2Function tool, we identified the enriched Gene Ontology (GO) terms and pathways associated with these lncRNAs (Supplementary Tables 9-12 , available at Carcinogenesis Online). It emerged that candidate lncRNAs were mainly involved in immune system, in receptor activities and in processes located at cellular membrane. Moreover, we used the recently developed FARNA tool in order to identify lncRNAs associated with PDAC. Many lncRNAs show a statistically significant association with PDAC, confirming their potential role in cancer development (Supplementary Table 13 , available at Carcinogenesis Online).
miRNAs targeting hub lncRNAs are involved in pancreatic cancer pathway.
Since some lncRNAs were recently observed acting as sponges to regulate specific miRNAs and therefore their target genes, resulting in the promotion of EMT, cells proliferation and migration in PDAC (31,32), we set out to analyse the lncRNAmiRNA-mRNA network in PDAC. Based on only experimentally supported miRNA-lncRNA interactions, we identified miRNAs targeting our 11 candidate lncRNA biomarkers (Supplementary  Table 14 , available at Carcinogenesis Online). Unfortunately, for LINC00675 and ITGB2-AS1 lncRNAs there was no experimental interaction data. Next, we also identified experimentally validated target genes regulated by these miRNAs and, based on these validated interactions, we performed a functional enrichment analysis in order to identify enriched KEGG pathways. We choose to exploit only experimental data avoiding prediction tools in order to obtain a higher reliability. The identified target genes were found to be significantly enriched in many cancer pathways, including 'Pancreatic Cancer' (P = 1.47E−09, rank = 6th, Supplementary Table 15, available at Carcinogenesis Online). Regarding this pathway, CCND1 (cyclin D1) and CDK6 (cyclin-dependent kinase 6) genes were targeted by the largest number of miRNAs, that is 49 and 39 out of 96, respectively. Moreover, we found that hsa-miR-34a-5p and hsa-miR-17-5p can target the largest number of mRNAs, that is 34 and 27 out of 62, respectively (Supplementary Tables 16-17, available at Carcinogenesis Online).
Candidate biomarkers are differentially expressed in normal and PDAC tissues
Next, we verified which lncRNAs, among 11 suggested and validated by WGCNA, were differentially expressed in normal pancreatic and PDAC tissues. To this aim, we used GEPIA tool to perform this analysis on an independent RNA-seq expression dataset, consisting of normal expression data from GTEx consortium and PDAC expression data from TCGA database.
Five lncRNAs (ITGB2-AS1, LINC00675, LINC01133, LINC01857, PSMB8-AS1) resulted significantly higher expressed in tumour than in normal samples (Figure 2 , P < 0.01). Therefore, these lncRNAs may be considered as diagnostic biomarker for PDAC.
Moreover, we performed a literature analysis exploiting data collected in Pancreatic Expression Database. A2M-AS1, DLEU2, LINC01133, MIR155HG, ITGB2-AS1 and PSMB8-AS1 are overexpressed in PDAC compared to healthy donor samples (P < 0.05), while differential expressions of LINC00675 and SLC25A25-AS1 are not significant (33) . Further studies reported the increased expression of LINC01133 and LINC00675 in PDAC tissues compared to normal samples, with fold changes = 2.5 and 672, respectively (34, 35) . Unfortunately, for the other lncRNAs there is no expression data.
Candidate lncRNAs are differentially methylated in normal and PDAC tissues
Methylation is a relevant epigenetic repression mechanism in transcription of both protein coding and non-coding genes. By using MethHC database, we verified if the promoters of candidate lncRNAs had an aberrant methylation patterns between normal and PDAC tissues. Based on TCGA data, A2M-AS1 and DLEU2 promoters were under-methylated in tumour samples, whereas MIR155HG, ITGB2-AS1, TSPOAP1-AS1 and LOC642852 promoters showed a significantly higher methylation level in PDAC than normal samples (Figure 3) . Therefore, the aberrantly methylation levels of these lncRNAs might serve as biomarkers for PDAC diagnosis.
Expression of some candidate biomarkers is dependent on copy number changes
Copy number alterations are common in cancer, where they can alter the expression of oncogenes (36) . Our results revealed that A2M-AS1, MIR155HG, SLC25A25-AS1 and TSPOAP1-AS1 lncRNAs were recurrently deleted in pancreatic cancer samples, whereas LINC01133 and LINC01857 were frequently amplified (Table 2) . Accordingly, their expression levels significantly correlate with their copy number in pancreatic cancer samples (Table 2 ). These findings suggest that copy number alterations contribute to lncRNA dysregulation in PDAC.
LncRNA candidate biomarkers stratify PDAC patients into high-and low-risk groups
In order to validate whether the proposed lncRNAs could be also prognostic PDAC biomarkers, we identified lncRNAs with the most significant association with OS and disease-free survival in PDAC patients. Survival analyses have been performed by using GEPIA tool that is based on an independent RNA-seq expression dataset of 171 PDAC patients. In Figure 4 , the Kaplan-Meier survival plots for OS are shown for each significant lncRNA able to stratify PDAC patients into high-and low-risk groups. In particular, we found that high expression of LINC01133 [HR = 1.6, p(HR) = 0.028, p(Logrank) = 0.026] was significantly associated with a shorter OS, suggesting that this lncRNA is biomarkers for poor prognosis of PDAC. Conversely, high-expression levels of the A2M-AS1 [HR = 0.59, p(HR) = 0.014, p(Logrank) = 0.013], TSPOAP1-AS1, also known as BZRAP1-AS1, [HR = 0.52, p(HR) = 0.0025, p(Logrank) = 0.0021] and LINC00205 [HR = 0.58, p(HR) = 0.01, p(Logrank) = 0.0091] lncRNAs were found to correlate with a better OS. Instead, regarding diseasefree survival, no lncRNA resulted to be a reliable prognostic biomarker.
Discussion
Currently, there are no accurate diagnostic biomarkers for the PDAC, a common cause of death from cancer with typically a very poor prognosis. Since lncRNAs, a novel class of regulatory RNAs, have been shown to be involved also in cancer biology, here we investigated their potential role as diagnostic/prognostic biomarkers or therapeutic targets in PDAC. In particular, we applied the WGCNA to existing microarray lncRNA expression data obtained from pancreatic tissues of PDAC patients and healthy subjects. For result validation, we performed WGCNA analysis on another independent lncRNA expression dataset and selected only 11 common lncRNAs able to significantly distinguish normal from PDAC conditions. Interestingly, among them, LINC01133 resulted to be significantly overexpressed in all microarray datasets we used, according to MA and Volcano plots. For each microarray probe, gene annotations are provided.
(*) 228909_at probe corresponds to both LOC642852 and LINC00205 lncRNAs, while 1559957_a_at only to LOC642852. In fact, LINC00205 shares some exons with LOC642852. Therefore, here we considered these lncRNAs together.
Since to date only a few lncRNAs associated with pancreatic cancer have been identified, we performed several analyses by using recently developed tools and based on publicly available data in order to characterise the identified lncRNAs. Our investigations showed that the identified lncRNAs were enriched in immune system related pathways, that are known to play a complex role in the development and progression of pancreatic cancer (37) . Moreover, we found that most of candidate lncRNAs were predicted to be related to the 'Pancreatic Cancer' pathway and that also miRNAs targeting our lncRNAs are involved in many cancer pathways, particularly pancreatic cancer. Interestingly, the miRNAs that we identified as mainly involved in this 'Pancreatic Cancer' pathway, i.e. miR-34a and miR-17, are associated with a poor prognosis in PDAC patients and involved in cancer cell proliferation by altering cell cycle (38, 39) . Accordingly, their main target genes, i.e. CCND1 (cyclin D1) and cyclin-dependent kinase 6 (CDK6), are key regulatory elements in cell cycle progression and proliferation.
Expression analyses showed that 9 out of 11 lncRNAs are significantly overexpressed in PDAC compared to normal samples. In order to reveal the molecular mechanisms underlying this general lncRNA overexpression, we set out to investigate the methylation level of lncRNA promoters and their CNA patterns.
As expected, A2M-AS1 and DLEU2 showed an inverse correlation between methylation levels and expression. However, TCGA data showed that ITGB2-AS1 is overexpressed in PDAC compared to normal samples but its promoter is also highly methylated in PDAC. Maybe, further molecular mechanisms could explain these results. Overall, since six lncRNAs showed significantly different methylation levels of their promoters, this epigenetic mechanism represents an interesting parameter to be assessed and may serve as biomarkers for PDAC diagnosis. Indeed, in breast cancer, it was observed that some lncRNAs can serve as biomarkers based on the methylation level of their promoters (40) . Our results showed also that six lncRNAs are frequently amplified or deleted in PDAC samples and, accordingly, over-or under-expressed. It is known that, in human cancers, many oncogenes and tumour suppressor genes are frequently amplified and deleted, respectively, but they do not lie in all genomic regions with copy number alterations. Therefore, many recurrent CNA patterns observed in human cancers remain unexplained (36) . Interestingly, localization of our six lncRNAs to CNA regions makes them particularly intriguing to study, in order to assess their potential role as oncogenes or tumour suppressor genes. Finally, our results also indicate that A2M-AS1, LINC01133, LINC00205 and TSPOAP1-AS1 lncRNAs could be used as biomarkers for PDAC patients' prognosis prediction. Among the candidate lncRNAs, some have been already demonstrated to be related to PDAC. In fact, LINC00675 may function as an oncogene, since its overexpression in PDAC tissues correlated with metastasis, invasion and poor survival and, at functional level, knockdown of LINC00675 can attenuate pancreatic cancer cell proliferation and invasion (34) . Accordingly to our data, it was recently observed that also LINC01133 is higher expressed in PDAC than in normal tissues and associated with worse OS in PDAC patients. Moreover, LINC01133 knockdown decreased PDAC cell proliferation both in vitro and in vivo (35) . Accordingly, LINC01133 was found to be significantly higher expressed in PDAC samples compared to normal tissues (33) . It was also found that some of our lncRNA biomarkers, including A2M-AS1, DLEU2, MIR155HG, ITGB2-AS1 and PSMB8-AS1 were higher expressed in PDAC patients than controls (33) . Very recently, several lncRNAs differentially expressed between PDAC epithelium and non-neoplastic stromal cells have been identified by laser capture microdissection of biopsies (41) . Interestingly, three of our candidate lncRNA biomarkers, namely LINC00675, LINC01133 and SLC25A25-AS1 are specifically expressed in the neoplastic epithelia, suggesting a role as regulators of molecular pathways altered in tumour cells.
Increasing evidences showed that some of our candidate lncRNAs can be considered as biomarkers in other tumours, encouraging researchers to assess their role also in PDAC. For example, it was shown that higher expression of DLEU2 was associated with a poor prognosis for clear cell renal cell carcinoma (ccRCC) patients (42) . Recently, LINC01133 has been suggested as diagnostic and prognostic biomarker in several cancer types (43, 44) . Its molecular mechanisms of tumorigenesis include the increase of cells proliferation, migration, invasion, EMT induction and the action as a sponge for the tumour suppressor miR-422a (43, 44) . Increased MIR155HG expression has been associated with the advanced stages and poor prognosis of glioma patients and, at functional level, it was involved in cell proliferation, migration, invasion and EMT promotion (45, 46) . Furthermore, hepatocellular carcinoma patients with higher LINC00205 expression levels showed shorter relapse-free survival time (47) . In addition, ITGB2-AS1 was significantly overexpressed in nasopharyngeal carcinoma (48) . Unlike the above-mentioned lncRNAs overexpressed in cancers, SLC25A25-AS1 is downregulated in tissues and sera of colorectal cancer patients and plays a tumour suppressive role by inhibiting EMT, cell proliferation and chemoresistance to 5-FU and doxorubicin (49) . Interestingly, it was found that TSPOAP1-AS1 was differentially alternative spliced between lung cancer and normal RNA-seq samples (50) . In this regard, it could be interesting to explore the role of RNA-binding proteins in driving the alternative splicing of this lncRNA (51) . Moreover, a genome-wide association study (GWAS) investigating the association with susceptibility to PDAC identified the rs2257205 single nucleotide polymorphism, located downstream to TSPOAP1-AS1 lncRNA gene (52) . Along with the lncRNA location within LINC00675 resulted to be not significantly differentially methylated, while for the other lncRNAs no data are available.
CNAs, their proximity to polymorphisms identified in genomewide association study represents a relevant genomic feature. Therefore, the involved lncRNAs are worthy of further molecular investigations, in particular by highlighting the polymorphism effects on splicing patterns and miRNA-binding sites (53) . Moreover, it would be of great interest to understand how they promote proliferation, metastasis and drug resistance or reduce apoptosis in PDAC. However, the lack of in vitro and in vivo identification of the mechanisms of action of suggested lncRNAs is a limitation of our study. For example, it is possible that the suggested lncRNAs epigenetically up-regulate or silence genes by reprogramming chromatin states. Alternatively, they can function as competing endogenous RNAs by sponging miRNAs and so can up-regulate the translation of the related mRNAs. They could also bind proteins and alter their stability and localization or mask their phosphorylation sites. Finally, it would be interesting to identify the stimuli and the signalling pathways involved in their expression regulation. In summary, our analyses uncovered some lncRNAs that might play critical roles in PDAC development and progression. Among them, A2M-AS1, LINC01133, LINC00675, LINC00205 and TSPOAP1-AS1 lncRNAs are also associated with PDAC patients' prognosis. Therefore, they may be valuable candidates as diagnostic and prognostic biomarkers and potential therapeutic targets for PDAC. Although further experimental investigations are needed, lncRNAs represent a new and promising perspective in cancer biomarker research.
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